- Home
- ABOS
as 12-17-2024 4:00pm EST
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CHARLOTTESVILLE |
| Market Cap: | 138.8M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 268.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.91 - $5.09 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acumen Pharmaceuticals Inc. News
ABOS Breaking Stock News: Dive into ABOS Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
I-Mab Leads Our Spotlight On 3 US Penny Stocks
GlobeNewswire
22 days ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GuruFocus.com
a month ago
Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
Thomson Reuters StreetEvents
a month ago
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call
GlobeNewswire
a month ago
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
a month ago
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
GlobeNewswire
a month ago
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
GlobeNewswire
a month ago
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
Compare ABOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.